Takeda Pharmaceutical Company Limited

Tokyo Stock Exchange:4502.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 45.82 B

Share Price

USD 29.34

Avg Daily Volume

5,104,727

Change (1 day)

-0.64%

Change (1 year)

15.94%

Change (YTD)

10.14%

Takeda Pharmaceutical Company Limited Share Price Year-To-Date (YTD) return on June 20, 2025: 10.14%

Takeda Pharmaceutical Company Limited Share Price Year-To-Date (YTD) return is 10.14% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Takeda Pharmaceutical Company Limited 52-week low Share Price is USD 31.09 on June 20, 2025, which is 5.95% above the current Share Price.
Takeda Pharmaceutical Company Limited 52-week low Share Price is USD 25.65 on June 20, 2025, which is -12.58% below the current Share Price.
Takeda Pharmaceutical Company Limited average Share Price for the last 52 weeks is USD 28.25.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Tokyo Stock Exchange: 4502.T

Takeda Pharmaceutical Company Limited

CEO	Mr. Christophe Weber
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	1-1, Nihonbashi-Honcho 2-chome
Employees	49,281
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.